Matches in Nanopublications for { ?s ?p "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 30 of
30
with 100 items per page.
- NP914182.RAQhI70beuZ06A9SZBkxiGtlrs3KH15fhOjOubnB-zQ-o130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914182.RAQhI70beuZ06A9SZBkxiGtlrs3KH15fhOjOubnB-zQ-o130_provenance.
- NP605878.RARXbGA8WpgXM-19H4aSZWu-mit_MwxBb2dBsVl4qh_WM130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605878.RARXbGA8WpgXM-19H4aSZWu-mit_MwxBb2dBsVl4qh_WM130_provenance.
- NP873078.RARc2jtUUM2MLy8NsTpqctCEdpfj7ABbvciYKd6B8q1yA130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873078.RARc2jtUUM2MLy8NsTpqctCEdpfj7ABbvciYKd6B8q1yA130_provenance.
- NP873297.RASnnfTtbOGaesa2oUI4l1RJ0POnkmYutkqc7ZUD3VHz4130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873297.RASnnfTtbOGaesa2oUI4l1RJ0POnkmYutkqc7ZUD3VHz4130_provenance.
- NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978417.RAV75uBkYcoxBpeQiNhr5U_kl0lEStGta9KWdHdVxBEMI130_provenance.
- NP978649.RAbgTrUMiH8xTNVd2V1KgW5zSmm1A1sabwmZjTSXje1bY130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978649.RAbgTrUMiH8xTNVd2V1KgW5zSmm1A1sabwmZjTSXje1bY130_provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP288333.RAVxfWljWtsxS8iAIJ31A7FMMT1OONWW8x1zPtmWfQZp4130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288333.RAVxfWljWtsxS8iAIJ31A7FMMT1OONWW8x1zPtmWfQZp4130_provenance.
- NP288337.RAT-K3JHEFZjfDOOvvrMB-1fDQ5qgBeJ0Q0gabmKVLIac130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288337.RAT-K3JHEFZjfDOOvvrMB-1fDQ5qgBeJ0Q0gabmKVLIac130_provenance.
- NP288338.RAUMpxwXq102sOiZGjv2Mcbh7Pw0GOC6pJdB_-LKNU650130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288338.RAUMpxwXq102sOiZGjv2Mcbh7Pw0GOC6pJdB_-LKNU650130_provenance.
- NP288339.RAYLD5zez4EYrbO8ckhP9YtokHvmtVTwwNGdlPUGJ3QG8130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288339.RAYLD5zez4EYrbO8ckhP9YtokHvmtVTwwNGdlPUGJ3QG8130_provenance.
- NP288345.RAYZyoRjh0yr6N74kmCZzZhB7izdtpKeeAB__87xiOuEU130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288345.RAYZyoRjh0yr6N74kmCZzZhB7izdtpKeeAB__87xiOuEU130_provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP913904.RADC0OSOhw6TZ_0aEHecpkU7VxKFeNotVTla5kCCax8LU130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913904.RADC0OSOhw6TZ_0aEHecpkU7VxKFeNotVTla5kCCax8LU130_provenance.
- NP606136.RAtvtULfethI_acn-2sI6mTTRSIcXEpNfOxaqxhe0eukQ130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606136.RAtvtULfethI_acn-2sI6mTTRSIcXEpNfOxaqxhe0eukQ130_provenance.
- NP288332.RAoRe5rblER_YYWqTopNah5Zm580ru6h8H9jveC6H5Di4130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288332.RAoRe5rblER_YYWqTopNah5Zm580ru6h8H9jveC6H5Di4130_provenance.
- NP288335.RAnxmMkCuUzZTIENX5rSqitFfVnOuPhadkgHI5VnorjfY130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288335.RAnxmMkCuUzZTIENX5rSqitFfVnOuPhadkgHI5VnorjfY130_provenance.
- NP288340.RAhMI5D2H_ClDVE88FI6lXg6jyMxBFRqws6ZnOLqA2Me0130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288340.RAhMI5D2H_ClDVE88FI6lXg6jyMxBFRqws6ZnOLqA2Me0130_provenance.
- NP288341.RAhvzraldda5R8wkcCW6c_VH9fl6LbhXvrTHXVe1RYHc0130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288341.RAhvzraldda5R8wkcCW6c_VH9fl6LbhXvrTHXVe1RYHc0130_provenance.
- NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781328.RA3bL32LZ7P7XB7pp4BrqXf-szjxRpq2GMjM7lWhw-oR8130_provenance.
- NP781558.RA1ZlgCNjCCBrmx7djeYxXRjrnvWl5O3bHxXHTctHPIXU130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781558.RA1ZlgCNjCCBrmx7djeYxXRjrnvWl5O3bHxXHTctHPIXU130_provenance.
- NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_assertion description "[Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288334.RAw6OZHhC6Hh4dcz_n-81zog7whKlzM6hGPwC-VRQoFhc130_provenance.